Effect of bromocriptine on maturity onset diabetes

Area of Science:

• Endocrinology
• Metabolic Disorders

Background:

• Dopamine pathways influence glucose metabolism and hormonal regulation.
• Maturity-onset diabetes involves impaired glucose tolerance and hormonal imbalances.

Purpose of the Study:

• To investigate the effects of bromocriptine and metoclopramide on glucose tolerance in diabetics and normal subjects.
• To explore the relationship between dopamine modulation, prolactin, growth hormone, and insulin levels in glucose homeostasis.

Main Methods:

• Administration of dopamine agonist (bromocriptine) and antagonist (metoclopramide) to maturity-onset diabetics and healthy controls.
• Assessment of fasting blood glucose, glucose tolerance, insulin, prolactin, and growth hormone levels before and after drug administration.

Main Results:

• Bromocriptine lowered fasting blood glucose and improved glucose tolerance in diabetics, with initial improvement in controls.
• Metoclopramide caused minor glucose tolerance impairment in controls but not in diabetics.
• Both drugs affected prolactin levels; bromocriptine reduced them, while metoclopramide increased them, with no significant impact on insulin or growth hormone in diabetics.

Conclusions:

• Bromocriptine demonstrates a therapeutic effect on glucose metabolism in maturity-onset diabetes.
• The glucose-lowering action of bromocriptine may be mediated by prolactin reduction, independent of growth hormone changes.